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Rhodococcus equi, mainly known from veterinary med-
icine as a pathogen in domestic animals, can also cause 
infections in immunocompromised humans, especially in 
those with defects in cellular immunity. Alemtuzumab, an 
anti-CD52 monoclonal antibody, causes lymphocytopenia 
by eliminating CD52-positive cells. We report a patient in 
whom Rhodococcus equi infection developed after alemtu-
zumab therapy.
R
hodococcus equi is a soil-borne, asporogenous, non-
motile, obligate aerobe; it is also a facultative, intracel-
lular, gram-positive microorganism that can survive inside 
macrophages, the characteristic considered the basis for its 
pathogenicity (1). In foals and other domestic animals, it is 
an important respiratory and intestinal pathogen (2). Hu-
man infection with R. equi is rare but can occur in immuno-
compromised patients, especially those who have HIV in-
fection and a CD4+ cell count <100 × 106/L (3). The clinical 
manifestations are diverse, although 80% of patients have 
some pulmonary involvement (3). In recent decades, an in-
creased incidence of R. equi infections in humans has been 
reported. This increase may be due to the rising number 
of immunocompromised patients as a result of increasing 
numbers of organ transplantations and intensiﬁ  ed antitu-
mor chemotherapy. We describe a patient with T-prolym-
phocytic leukemia (T-PLL) in whom a febrile disease with 
lung abscess due to R. equi developed 10 weeks after the 
complete remission of leukemia was induced by chemo-
therapy combined with alemtuzumab.
Case Report
A 68-year-old man with T-PLL (leukocyte count 174.5 
× 109/L, 96% lymphoid cells) was treated with chemother-
apy consisting of cyclophosphamide, doxorubicin, vincris-
tine, and prednisolone every 2 weeks (CHOP14), in com-
bination with alemtuzumab 30 mg subcutaneously on days 
1, 5, and 9 of each cycle. This combined therapy was well 
tolerated. Complete cytologic and immunohistochemical 
remission was conﬁ  rmed by blood and bone marrow ex-
amination 2 weeks after the latest chemotherapy treatment. 
Ten weeks later, the patient experienced ﬂ  u-like symptoms 
and had a fever of 38.9°C. One week earlier, the antimicro-
bial prophylaxis, which consisted of valacyclovir, 500 mg 
2 times/day, and trimethoprim-sulfamethoxazole, 960 mg 3 
times/week, had been stopped, although the alemtuzumab-
induced lymphocytopenia was still present (leukocytes 7.2 
× 109/L, 84% neutrophils, 0.6% lymphocytes). Outpatient 
evaluation showed 2 lung abscesses. From 3 consecutive 
blood cultures and from the bronchoalveolar lavage ﬂ  uid, 
a gram-positive bacillus with mucoid growth was isolated 
and identiﬁ  ed as R. equi (API Coryne, bioMérieux, Marcy 
l’Etoile, France). The isolated strain was resistant to β-lac-
tam antimicrobial drugs and trimethoprim-sulfamethoxa-
zole and susceptible to aminoglycosides, tetracyclines, ﬂ  u-
oroquinolones, glycopeptides, erythromycin, and rifampin. 
Treatment with moxiﬂ   oxacin and rifampin was begun. 
After 3 weeks of treatment, fever developed in the patient 
again. Blood cultures grew R. equi. The patient was admit-
ted to the hospital for intravenous treatment with imipe-
nem/cilastatin, 500 mg/500 mg 3 times/day, and vancomy-
cin, 1.5 g once a day. A computed tomographic scan of the 
chest showed progression of the pulmonary abscesses and 
mediastinal lymphadenopathy. Clarithromycin, 500 mg 2 
times/day, was added, and the vancomycin was increased 
to 2 g once a day, which resulted in clinical improvement.  
Purple, subcutaneous, oval lesions, 2–3 cm in diameter and 
not painful to palpation, were seen on the upper portion 
of both legs. Pathologic examination of these lesions after 
biopsy showed suspected localization of T-PLL. R. equi 
could not be demonstrated in these skin lesions by either 
pathologic or microbiologic examination. After 2 weeks of 
receiving intravenous antimicrobial drugs, the patient was 
discharged with oral rifampicin, 600 mg once a day; cip-
roﬂ  oxacin, 750 mg twice/day; and azithromycin, 500 mg 
once a day. 
He was readmitted to our hospital 9 weeks later because 
he had become dyspneic and febrile. Evaluation showed 
pleural effusion on the right side. Progression of the T-PLL 
was also diagnosed. After 1 week’s incubation of the pleural 
ﬂ  uid, mucoid nonpigmented colonies were growing, consist-
ing of gram-positive coccoid rods, which were catalase posi-
tive. Rhodococcus infection was suspected and conﬁ  rmed by 
16S rDNA sequencing without further conventional identiﬁ  -
cation. The isolate showed intermediate susceptibility to cip-
roﬂ  oxacin (MIC 0.75 mg/L), moxiﬂ  oxacin (MIC 0.5 mg/L), 
and erythromycin (MIC 1.5 mg/L). Drainage of the pleural 
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ﬂ  uid resulted in a trapped lung due to pleural thickening. 
A pleurectomy was considered but was refused by the pa-
tient, considering his poor overall prognosis based on the 
relapse of T-PLL. On his request, the antimicrobial drugs 
were stopped, and he went home with palliative treatment 
consisting of morphine and prednisone. He died 3 months 
later. Overall, he had been treated with antimicrobial agents 
for 19 weeks.
Conclusions
The described patient acquired a R. equi infection dur-
ing alemtuzumab-induced lymphocytopenia. R. equi infec-
tion is predominantly airborne, acquired through the respi-
ratory tract. Exposure to domestic animals, such as horses 
and pigs, may play a role in acquisition of this organism. 
The patient denied any such contact, as do two thirds of all 
patients infected with R. equi (3).
Alemtuzumab is approved as a second-line treatment 
in chronic lymphatic leukemia and is increasingly used in 
therapeutic trials for T-cell malignancies. It is a recom-
binant DNA-derived, humanized monoclonal antibody 
directed against CD52 (4). CD52 is a membrane glyco-
protein expressed mainly by lymphocytes, especially T 
cells. Alemtuzumab causes lysis of these cells by binding 
to CD52, resulting in lymphocytopenia, which can persist 
for up to 320 days after treatment (5). While the patient is 
experiencing lymphocytopenia, prophylaxis with an antivi-
ral agent and trimethoprim-sulfamethoxazole are manda-
tory to prevent the most frequent opportunistic infections 
(6). Reduced cellular immunity is known to predispose to 
infection with R. equi (7). Primary prophylaxis is not rou-
tinely recommended because no data are available to sup-
port its efﬁ  cacy and because the infection is rare (3). Due to 
variable susceptibility to trimethoprim-sulfamethoxazole, 
the prophylaxis regimen used after alemtuzumab therapy 
will not prevent R. equi infection in all patients, as this case 
illustrates.
Standard treatment regimens for R. equi infections 
have not been established. Weinstock and Brown advised 
intravenous therapy with 2 or 3 drug regimens that include 
vancomycin, imipenem, aminoglycosides, ciproﬂ  oxacin, 
rifampin, or erythromycin (3). This recommendation was 
based on in vitro susceptibility data and published case re-
ports. Treatment should preferably be guided by suscepti-
bility testing. After clinical improvement (usually after 2–4 
weeks), oral antimicrobial agents can then be substituted 
and continued until all culture results are negative and the 
patient’s symptoms and signs have resolved. A minimum 
of 6 months of antimicrobial drug therapy is typically re-
quired for immunocompromised patients with pulmonary, 
bone and joint, or central nervous system infections (3).
Our patient started treatment with oral antibiotics, 
guided by susceptibility tests. Although moxiﬂ  oxacin and 
rifampin are known for their good oral resorption, and de-
spite initial clinical improvement, progression of the infec-
tion was apparent by the clinical course. Susceptibility test-
ing was not performed at this time, but testing later in the 
clinical course suggested a decrease in susceptibility by the 
R. equi strain to the antimicrobial agents given.
After this regimen failed, intravenous therapy with 3 
antimicrobial drugs was instituted. However, also this strat-
egy ultimately failed. Apart from persistence of bacilli due 
to poor penetration at the site of infection, and the possible 
development of resistance, this lack of response is likely 
due to persistent lymphocytopenia resulting from previous 
treatment with alemtuzumab and progression of T-PLL.
In summary, longstanding alemtuzumab-induced lym-
phocytopenia is the most likely cause of the uncontrollable 
opportunistic  R. equi infection in the described patient. 
This case illustrates the therapeutic challenges of this kind 
of infection in severely immunocompromised patients.
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